Meds for ALS

Research that reveals the fundamental cellular malfunction that underlies amyotrophic lateral sclerosis (ALS, known as motor neurone disease outside the US) and the related disease frontotemporal dementia could lead to pharmaceutical interventions that preserve neurones. The presence of a genetic mutation is the first discovery of its kind in that rather than harming enzymatic and protein pathways, an abnormal version of a protein involved in cellular phase separation occurs. Paul Taylor of St Jude's Children's Research Hospital and colleagues write in the journal Neuron how their findings could point to a way to restore the ability of neurons to disassemble the organelles when their cellular purpose has ended.